Banco Santander S.A. Reduces Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Banco Santander S.A. trimmed its stake in Johnson & Johnson (NYSE:JNJFree Report) by 2.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 123,858 shares of the company’s stock after selling 3,136 shares during the period. Banco Santander S.A.’s holdings in Johnson & Johnson were worth $19,291,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Hibernia Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $27,000. FNY Investment Advisers LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $37,000. Tower View Wealth Management LLC grew its stake in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after buying an additional 165 shares during the last quarter. Creative Capital Management Investments LLC grew its stake in Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth $48,000. 68.40% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on JNJ. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Tuesday, February 6th. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $176.14.

Read Our Latest Stock Analysis on JNJ

Johnson & Johnson Stock Up 0.2 %

Shares of JNJ opened at $156.76 on Monday. The company has a market capitalization of $377.37 billion, a price-to-earnings ratio of 11.35, a PEG ratio of 2.63 and a beta of 0.53. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. The stock’s 50-day moving average price is $158.20 and its 200-day moving average price is $158.73.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. Johnson & Johnson’s quarterly revenue was down 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.35 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be issued a $1.19 dividend. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s payout ratio is 34.47%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.